Merck Long Term Debt 2010-2024 | MRK
Merck long term debt from 2010 to 2024. Long term debt can be defined as the sum of all long term debt fields.
- Merck long term debt for the quarter ending September 30, 2024 was $34.982B, a 2.97% increase year-over-year.
- Merck long term debt for 2023 was $33.683B, a 17.18% increase from 2022.
- Merck long term debt for 2022 was $28.745B, a 6.34% decline from 2021.
- Merck long term debt for 2021 was $30.69B, a 21.02% increase from 2020.
Merck Annual Long Term Debt
(Millions of US $) |
| 2023 |
$33,683 |
| 2022 |
$28,745 |
| 2021 |
$30,690 |
| 2020 |
$25,360 |
| 2019 |
$22,736 |
| 2018 |
$19,806 |
| 2017 |
$21,353 |
| 2016 |
$24,274 |
| 2015 |
$23,829 |
| 2014 |
$18,699 |
| 2013 |
$20,539 |
| 2012 |
$16,254 |
| 2011 |
$15,525 |
| 2010 |
$15,482 |
| 2009 |
$16,095 |
Merck Quarterly Long Term Debt
(Millions of US $) |
| 2024-09-30 |
$34,982 |
| 2024-06-30 |
$34,717 |
| 2024-03-31 |
$31,142 |
| 2023-12-31 |
$33,683 |
| 2023-09-30 |
$33,972 |
| 2023-06-30 |
$34,072 |
| 2023-03-31 |
$28,074 |
| 2022-12-31 |
$28,745 |
| 2022-09-30 |
$28,482 |
| 2022-06-30 |
$28,684 |
| 2022-03-31 |
$30,586 |
| 2021-12-31 |
$30,690 |
| 2021-09-30 |
$22,907 |
| 2021-06-30 |
$24,033 |
| 2021-03-31 |
$24,002 |
| 2020-12-31 |
$25,360 |
| 2020-09-30 |
$26,321 |
| 2020-06-30 |
$26,156 |
| 2020-03-31 |
$21,637 |
| 2019-12-31 |
$22,736 |
| 2019-09-30 |
$22,677 |
| 2019-06-30 |
$22,771 |
| 2019-03-31 |
$22,721 |
| 2018-12-31 |
$19,806 |
| 2018-09-30 |
$19,936 |
| 2018-06-30 |
$19,959 |
| 2018-03-31 |
$21,501 |
| 2017-12-31 |
$21,353 |
| 2017-09-30 |
$21,838 |
| 2017-06-30 |
$21,706 |
| 2017-03-31 |
$23,437 |
| 2016-12-31 |
$24,274 |
| 2016-09-30 |
$23,656 |
| 2016-06-30 |
$23,642 |
| 2016-03-31 |
$23,656 |
| 2015-12-31 |
$23,829 |
| 2015-09-30 |
$24,124 |
| 2015-06-30 |
$24,069 |
| 2015-03-31 |
$25,506 |
| 2014-12-31 |
$18,699 |
| 2014-09-30 |
$18,566 |
| 2014-06-30 |
$18,590 |
| 2014-03-31 |
$19,589 |
| 2013-12-31 |
$20,539 |
| 2013-09-30 |
$22,647 |
| 2013-06-30 |
$22,526 |
| 2013-03-31 |
$16,089 |
| 2012-12-31 |
$16,254 |
| 2012-09-30 |
$17,571 |
| 2012-06-30 |
$15,057 |
| 2012-03-31 |
$15,228 |
| 2011-12-31 |
$15,525 |
| 2011-09-30 |
$15,692 |
| 2011-06-30 |
$15,783 |
| 2011-03-31 |
$15,644 |
| 2010-12-31 |
$15,482 |
| 2010-09-30 |
$14,032 |
| 2010-06-30 |
$13,835 |
| 2010-03-31 |
$15,281 |
| 2009-12-31 |
$16,095 |
| 2009-09-30 |
$8,205 |
| 2009-06-30 |
$8,181 |
| 2009-03-31 |
$3,939 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$251.749B |
$60.115B |
|
Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.
|
